BIOLARGO, INC.
For the period ended Dec 31, 2024. Filed Mar 31, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 31, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Market Information
Since January 23, 2008, our common stock has been quoted on the OTC Markets (formerly known as the “OTC Bulletin Board”) under the trading symbol “BLGO”. Since May 2024, it has listed on the OTCQX, the OTC Market's highest marketplace. The OTC Markets is a regulated quotation service that displays real-time quotes, last-sale prices and volume information in over-the-counter equity securities. OTCQX securities are traded by a community of market makers that enter quotes and trade reports. This market is limited in comparison to the national stock exchanges and any prices quoted may not be a reliable indication of the value of our common stock. Any over-the-counter market quotations reflect inter-dealer prices, without retail mark-up, mark-down or commission and may not necessarily represent actual transactions.
Holders
As of March 28, 2025, there were approximately 530 registered holders of our common stock, and 5,300 beneficial owners.
Dividends
We have never declared or paid a cash dividend to stockholders. We intend to retain any earnings which may be generated in the future to finance operations.
Securities Authorized for Issuance Pursuant to Equity Compensation Plans
Equity Compensation Plan Information as of December 31, 2024
| Number of securities to be · Weighted average | |||
|---|---|---|---|
| issued upon exercise of | exercise price of | Number of securities | |
| outstanding options, | outstanding options, | remaining available for | |
| warrants and rights | warrants and rights | future issuance | |
| Plan Category | (a) | (b) | (c) |
| Equity compensation plans approved by security holders | 48,822,806 | $0.20 | 34,506,080 |
| Equity compensation plans not approved by security holders(2) | 15,687,642 | $0.40 | n/a |
| Warrants | 31,615,616 | $0.29 | n/a |
| Total | 96,126,064 | $0.26 | 34,506,080 |
| (1) | Includes 1,157,500 shares issuable under the 2007 Equity Plan, which expired September 6, 2017; includes 42,171,386 shares issuable under the 2018 Equity Incentive Plan which expired March 2024; includes 5,493,920 shares issuable under the 2024 Equity Plan, adopted by our stockholders June 13, 2024. |
| (2) | This includes various issuances of options to specific individuals either as a conversion of un-paid obligations pursuant to a plan adopted by our board of directors, or as part of their agreement for services. |
Sales of Unregistered Securities
The following is a report of the sales of unregistered securities in the past two years not previously reported in a Quarterly Report on Form 10-Q or in a Current Report on Form 8-K.
During 2024, Clyra Medical sold shares of its common stock and warrants and received $2,005,000 gross proceeds from 29 accredited investors, and in exchange issued the investors 373,835 shares of its common stock and a warrant to purchase 205,670 shares of common stock at $7.50 per share.
All of these offerings and sales were made in reliance on the exemption from registration contained in Section 4(2) of the Securities Exchange Act and/or Regulation D promulgated thereunder as not involving a public offering of securities.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.